181065-46-3 Usage
Uses
Used in Medical Imaging Industry:
p-NH2-Bn-DOTA(B-200) is used as a bifunctional chelator for the preparation of gadolinium complexes as MRI blood contrast agents. Its ability to form stable complexes with gadolinium enhances the contrast of MRI scans, leading to improved diagnostic accuracy and visualization of blood vessels and other internal structures. This application is particularly useful in detecting and diagnosing various medical conditions, such as tumors, vascular diseases, and other abnormalities within the body.
Check Digit Verification of cas no
The CAS Registry Mumber 181065-46-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,1,0,6 and 5 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 181065-46:
(8*1)+(7*8)+(6*1)+(5*0)+(4*6)+(3*5)+(2*4)+(1*6)=123
123 % 10 = 3
So 181065-46-3 is a valid CAS Registry Number.
181065-46-3Relevant academic research and scientific papers
Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in human breast cancer cells
Saha, Pijus,H?dl, Claudia,Strauss, Wolfgang S.L.,Steiner, Rudolf,Goessler, Walter,Kunert, Olaf,Leitner, Alexander,Haslinger, Ernst,Schramm, H. Wolfgang
experimental part, p. 1891 - 1898 (2010/05/17)
Novel gadolinium-based mifepristone conjugates were synthesised using various synthetic routes. Moderate antiprogestagenic activity of the new conjugates was observed in human breast cancer cells (T47-D cells) using AP (alkaline phosphatase) assay. The amount of incorporated Gd determined by inductively coupled plasma mass spectroscopy (ICPMS) indicates the number of binding sites per cell. These conjugates might be important compounds to develop receptor-targeted MRI contrast agents as well as other anti-breast cancer therapeutics.
